scholarly journals Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target

2018 ◽  
Vol 12 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Athanasios Skarmoutsos ◽  
Ioannis Skarmoutsos ◽  
Ioannis Katafigiotis ◽  
Elisavet Tataki ◽  
Athina Giagini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Characteristic Curve ◽  
Specific Antigen ◽  
Predictive Ability ◽  
Platelet Derived Growth Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Transrectal Biopsy

Introduction: Although the prostate specific antigen revolutionized the diagnosis of prostate cancer (PCa), it has its limitations. We prospectively examined the potential use of the platelet-derived growth factor-BB (PDGF-BB) as a urine biomarker for the early diagnosis of PCa. Materials and Methods: The urine samples of 118 patients were collected after a prostatic massage and all the patients subsequently underwent ultrasound-guided transrectal biopsy. PDGF-BB was detected in the urine by enzyme-linked immunosorbent assay. Results: Patients with PCa had greater levels of prostate specific antigen and PDGF-BB. Receiver operating characteristic curve analysis showed that the optimal cut-of of PDGF-BB for the prediction of PCa was 1,504.9 with a sensitivity of 60% and a specificity of 51.3%. For a 100 unit increase in PDGF-BB, the likelihood for PCa increased about 4%. Conclusion: PDGF-BB showed a significant predictive ability for PCa. Detection of PDGF-BB in urine with Elisa was easy and improved our diagnostic accuracy in the diagnosis of PCa.

scholarly journals Prostate-Specific Antigen: From Promising to Disappointment Tool for Diagnosis of Chronic Renal Failure in Predialysis Patients

2021 ◽  
Vol 07 (02) ◽  
pp. 082-084
Author(s):  
Ali Abdul Hussein S Al-Janabi
Keyword(s):  
Prostate Cancer ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Enzyme Linked Immunosorbent Assay ◽  
Elderly Men ◽  
A Value ◽  
Total Psa ◽  
Moderate Elevation

Abstract Introduction Prostate-specific antigen (PSA) is a biomarker commonly used for detection of prostate cancer. Its viability as a marker for diagnosis of chronic renal failure (CRF) in predialysis patients was investigated. Methods Sera from 230 patients with CRF were analyzed by enzyme-linked immunosorbent assay (ELISA) for determining total PSA (tPSA) levels before hemodialysis. Results Of the patients investigated, 98.69% had a normal PSA level with a value less than 4 ng/mL. Three elderly men with both kidney failure showed a moderate elevation of PSA level. Conclusion PSA is considered a nonsignificant indicator for diagnosis of CRF.

Naujų prostatos specifinio antigeno izoformų reikšmė ankstyvajai prostatos vėžio diagnostikai

2021 ◽  
Author(s):  
◽  
Marija Barisienė
Keyword(s):  
Prostate Cancer ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Specific Antigen

Significance of new prostate-specific antigen isoforms for early diagnosis of prostate cancer

scholarly journals Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer

2021 ◽  
Author(s):  
Shotaro Nakanishi ◽  
Masato Goya ◽  
Mitsuyoshi Tamaki ◽  
Takuma Oshiro ◽  
Seiichi Saito
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Prostate Specific Antigen ◽  
Characteristic Curve ◽  
Specific Antigen ◽  
Predictive Marker ◽  
Castration Resistant Prostate Cancer ◽  
Pretreatment Level ◽  
Castration Resistant ◽  
Hormone Sensitive

Abstract Objective: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients. Results: In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥8 (p = 0.004), an extent of disease value (EOD) of ≥2 (p = 0.004), and a 3-month PSA level >1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. For OS, a 3-month PSA level >1% of the pretreatment level was an independent predictor of time to CRPC (p = 0.004).Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level >1% of the pretreatment level correlated with poor a prognosis.

scholarly journals Catching the Sugars: Electrochemical Aptasensors for the Detection of Cancer-Related Glycosylation Changes in Prostate-Specific Antigen

Proceedings ◽  
2020 ◽  
Vol 60 (1) ◽  
pp. 47
Author(s):  
Ana Díaz-Fernández ◽  
Rebeca Miranda-Castro ◽  
Pedro Estrela ◽  
Noemí de-los-Santos-Álvarez ◽  
María Jesús Lobo-Castañón
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
False Positives ◽  
High Rate ◽  
Enzyme Linked Immunosorbent Assay ◽  
Glycan Structure ◽  
Specific Cancer ◽  
Different Levels ◽  
Selection Of

Prostate-specific Antigen (PSA) is the biomarker that is used for prostate cancer (PCa) detection, although its lack of specificity results in a high rate of false-positives and many unnecessary biopsies. Therefore, there is a need for more specific cancer biomarkers for PCa. Recent studies have shown that the aberrant glycosylation of proteins is a common feature of the presence of cancer. In the case of prostate cancer, there are changes in core-fucose and sialic acids in the glycan structure of PSA. In this work, we describe two different strategies to direct the selection of aptamers toward the glycans of PSA. From these strategies, we identified two aptamers (PSA-1 and PSAG-1) that bind to the glycan structure of PSA with high affinity. Both aptamers were applied in the design of electrochemical aptasensors, in sandwich and direct formats, in order to detect the changes in the glycosylation of PSA. The sensors responded to different levels of PSA in serum, and they showed higher potential to discriminate clinically-meaningful PCa than the ELISA (Enzyme-linked immunosorbent assay) test used in hospitals (reducing the number of false positives), although validation on more samples is needed.

scholarly journals PSA screening for prostate cancer

2017 ◽  
Vol 63 (8) ◽  
pp. 722-725 ◽  
Author(s):  
Marcus V. Sadi
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Low Grade ◽  
Psa Screening ◽  
Psa Testing ◽  
Baseline Values

Summary Screening of prostate cancer with prostate-specific antigen (PSA) is a highly controversial issue. One part of the controversy is due to the confusion between population screening and early diagnosis, another derives from problems related to the quality of existing screening studies, the results of radical curative treatment for low grade tumors and the complications resulting from treatments that affect the patient’s quality of life. Our review aimed to critically analyze the current recommendations for PSA testing, based on new data provided by the re-evaluation of the ongoing studies and the updated USPSTF recommendation statement, and to propose a more rational and selective use of PSA compared with baseline values obtained at an approximate age of 40 to 50 years.

Value of Prostate Specific Antigen in Early Diagnosis of Prostate Cancer: Study of Men Born in 1913

1995 ◽  
Vol 154 (4) ◽  
pp. 1386-1389 ◽  
Author(s):  
Gosta Tibblin ◽  
Lennart Welin ◽  
Reinhold Bergstrom ◽  
Gunnar Ronquist ◽  
Bo-Johan Norlen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Diagnosis ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Cancer Study ◽  
Prostate Cancer Study

scholarly journals Blood cadmium levels increase prostate specific antigen and insulin-like growth factor-1 among cadmium exposed workers

2017 ◽  
Vol 36 (1) ◽  
pp. 42 ◽  
Author(s):  
Nendyah Roestijawati ◽  
Lintje Setyawati Maurits ◽  
Sugiyanto Sugiyanto
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Absorption Spectrometry ◽  
Cross Sectional ◽  
Exposed Workers ◽  
Spearman Correlation Test ◽  
Relationship Of ◽  
The Relationship

<p>BACKGROUND<br />Cadmium (Cd) is a heavy metal that is classified as a human carcinogen (group IA), one of the cancers that it can cause being prostate cancer. The development of prostate cancer on a molecular basis involves oncogenes such as insuline-like growth factor-1 (IGF-1). Prostate cancer can be detected in the laboratory through the examination of prostate specific antigen (PSA). The present study aimed to determine the relationship of Cd levels with levels of PSA and IGF-1 in exposed and unexposed workers.</p><p>METHODS<br />The study design was cross sectional. The subjects of the studycame from two groups of workers, ie. the group of Cd exposed workers who were welding shop workers and the group of unexposed workers who were office workers. The minimum samplesize was 85 people. The independent variable was blood Cd level. The dependent variables were PSA and IGF-1 levels. Blood Cd levels were measured by atomic absorption spectrometry (AAS), while PSA and IGF-1 were measured using ELISA. Data analysis was performed using the Mann-Whitney test and the Spearman correlation test.</p><p>RESULTS<br />Mean blood Cd level in the exposed workers was 6.5 mg/L and in the unexposed workers 2.15 mg/L. There was a relationship between blood Cd and PSA levels (p&lt;0.05) and between blood Cd levels and IGF-1 (p &lt;0.05).</p><p>CONCLUSIONS<br />There was a relationship of blood Cd with PSA and IGF-1 levels.among workers. PSA and IGF-1 could be a biochemical markers of disease control in cadmium exposed workers.</p>

Sign in / Sign up

Export Citation Format

Share Document